Regulatory Agency (original) (raw)
Latest News for: regulatory agency
Nipocalimab (Imaavy) authorised to treat adults and adolescents with generalised myasthenia gravis (MHRA - Medicines and Healthcare products Regulatory Agency)
Public Technologies 09 Jun 2026
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (9 June 2026) authorised the medicine nipocalimab (Imaavy) to treat adults and adolescents aged 12 years and older with generalised myasthenia gravis (gMG).
MHRA launches AI sandbox to accelerate medicines development and improve safety (MHRA - Medicines and Healthcare products Regulatory Agency)
Public Technologies 09 Jun 2026
The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating all medicines and medical devices in the UK by ensuring they work and are acceptably safe.
Advertising investigations: May 2026 (MHRA - Medicines and Healthcare products Regulatory Agency)
Public Technologies 08 Jun 2026
MHRA - Medicines and Healthcare products Regulatory Agency published this content on ...
MHRA review of the benefits and risks of avacopan (MHRA - Medicines and Healthcare products Regulatory Agency)
Public Technologies 05 Jun 2026
MHRA - Medicines and Healthcare products Regulatory Agency published this content on June 05, 2026, and is solely responsible for the information contained herein.
MHRA Public Sector Equality Duty Report 2025-2026 (MHRA - Medicines and Healthcare products Regulatory Agency)
Public Technologies 04 Jun 2026
This report outlines how the Medicines and Healthcare products Regulatory Agency (MHRA) meets our obligations under the Public Sector Equality Duty (PSED), as set out in section 149 of the Equality Act 2010 (the Act).
Adjuvanted trivalent influenza vaccine authorised for adults aged 50 and over (MHRA - Medicines and Healthcare products Regulatory Agency)
Public Technologies 04 Jun 2026
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (4 June 2026) granted a marketing authorisation for the adjuvanted trivalent influenza vaccine (Aujemflu) to protect adults aged 50 and over against flu.
Resmetirom (Rezdiffra) authorised to treat metabolic dysfunction-associated steatohepatitis (MASH) in adults (MHRA - Medicines and Healthcare products Regulatory Agency)
Public Technologies 03 Jun 2026
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (3 June 2026) authorised the medicine resmetirom (Rezdiffra) to treat adult patients with metabolic dysfunction-associated steatohepatitis (MASH).
Rilzabrutinib authorised to treat adults with immune thrombocytopenia when prior treatments have been insufficient (MHRA - Medicines and Healthcare products Regulatory Agency)
Public Technologies 29 May 2026
The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating all medicines and medical devices in the UK by ensuring they work and are acceptably safe.
Two arrested during the MHRA’s largest ever seizure of unlicensed weight loss medicines (MHRA - Medicines and Healthcare products Regulatory Agency)
Public Technologies 29 May 2026
... of such products by the agency ... MHRA - Medicines and Healthcare products Regulatory Agency published this content on May 29, 2026, and is solely responsible for the information contained herein.
Precautionary recall of blood pressure medication (Crescent Pharma Limited Ramipril 2.5mg capsules) after packaging error (MHRA - Medicines and Healthcare products Regulatory Agency)
Public Technologies 28 May 2026
) ... The MHRA is an executive agency of the Department of Health and Social Care ... MHRA - Medicines and Healthcare products Regulatory Agency published this content on May 28, 2026, and is solely responsible for the information contained herein ... (noodl.
MHRA welcomes Jason Bonander as he starts his role as Chief Digital and Technology Officer (MHRA - Medicines and Healthcare products Regulatory Agency)
Public Technologies 27 May 2026
The Medicines and Healthcare products Regulatory Agency (MHRA) welcomes Jason Bonander, who starts his role as the MHRA's Chief Digital and Technology Officer (CDTO) today (27 May 2026).
Don’t let this heatwave affect your medicines: Three important tips from the MHRA (MHRA - Medicines and Healthcare products Regulatory Agency)
Public Technologies 26 May 2026
As the UK braces for another scorching day of high temperatures today, the Medicines and Healthcare products Regulatory Agency (MHRA) is reminding people that these hot conditions can affect medicines and how well they work.
Draft rare disease therapies regulatory framework (MHRA - Medicines and Healthcare products Regulatory Agency)
Public Technologies 21 May 2026
These factors make traditional regulatory routes difficult or impossible to use ... MHRA - Medicines and Healthcare products Regulatory Agency published this content on May 21, 2026, and is solely responsible for the information contained herein.
MHRA consults on new regulatory framework to make UK a global leader in rare disease therapy development (MHRA - Medicines and Healthcare products Regulatory Agency)
Public Technologies 21 May 2026
Medicines and Healthcare products Regulatory Agency, National Institute for Health and Care Excellence, Department for Health and Social Care, NHS England.
Landmark new plans bring treatments for rare diseases a step closer (MHRA - Medicines and Healthcare products Regulatory Agency)
Public Technologies 21 May 2026
Today, the Medicines and Healthcare products Regulatory Agency (MHRA) launches a landmark public consultation on a proposed new regulatory framework that will spearhead the development of rare disease treatment in the UK.